Evidence map›Paper›PMID 28719595›Full record

ArticleThe American journal of gastroenterology2017

Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab.

Akihiro Yamada, Yuga Komaki, Nayan Patel, Fukiko Komaki, Arthur S Aelvoet, Anthony L Tran, Joel Pekow, Sushila Dalal, Russell D Cohen, Lisa Cannon and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in The American journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 7 pooled it
12.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 7 syntheses or guidelines pooled it, 93 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Review
  9. Review
  10. Article
  11. Review
  12. Perioperative optimization of Crohn's disease.Annals of gastroenterological surgery · 2023
    Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Akihiro YamadaSection of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, Illinois, USA.
Yuga KomakiSection of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, Illinois, USA.
Nayan PatelNew York Medical College, Valhalla, New York, USA.
Fukiko KomakiSection of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, Illinois, USA.
Arthur S AelvoetSection of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, Illinois, USA.
Anthony L TranSection of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, Illinois, USA.
Joel PekowSection of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, Illinois, USA.
Sushila DalalSection of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, Illinois, USA.
Russell D CohenSection of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, Illinois, USA.
Lisa CannonSection of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, Illinois, USA.
Konstantin UmanskiySection of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, Illinois, USA.
Radhika SmithSection of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, Illinois, USA.
Roger HurstSection of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, Illinois, USA.
Neil HymanSection of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, Illinois, USA.
David T RubinSection of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, Illinois, USA.
Atsushi SakurabaSection of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, Illinois, USA.
University of Chicago · USNew York Medical College · US

Funding

Novel microRNA regulatory networks predictive of colon carcinogenesis in IBDK08DK090152 · NIDDK · UNIVERSITY OF CHICAGO · PI PEKOW, JOEL · 2012 to 2016
$732k
NIDDK NIH HHS K08 DK090152
6 · The paper itself

Abstract

objectivesVedolizumab is increasingly used to treat patients with ulcerative colitis (UC) and Crohn's disease (CD), however, its safety during the perioperative period remains unclear. We compared the 30-day postoperative complications among patients treated preoperatively with vedolizumab, anti-tumor necrosis factor (TNF)-α agents or non-biological therapy.

methodsThe retrospective study cohort was comprised of patients receiving vedolizumab, anti-TNF-α agents or non-biological therapy within 4 weeks of surgery. The rates of 30-day postoperative complications were compared between groups using univariate and multivariate analysis. Propensity score-matched analysis was performed to compare the outcome between groups.

resultsAmong 443 patients (64 vedolizumab, 129 anti-TNF-α agents, and 250 non-biological therapy), a total of 144 patients experienced postoperative complications (32%). In multivariate analysis, age >65 (odds ratio (OR) 3.56, 95% confidence interval (CI) 1.30-9.76) and low-albumin (OR 2.26, 95% CI 1.28-4.00) were associated with increased risk of 30-day postoperative complications. For infectious complications, steroid use (OR 3.67, 95% CI 1.57-8.57, P=0.003) and low hemoglobin (OR 3.03, 95% CI 1.32-6.96, P=0.009) were associated with increased risk in multivariate analysis. Propensity score matched analysis demonstrated that the risks of postoperative complications were not different among patients preoperatively receiving vedolizumab, anti-TNF-α agents or non-biological therapy (UC, P=0.40; CD, P=0.35).

conclusionsIn the present study, preoperative vedolizumab exposure did not affect the risk of 30-day postoperative complications in UC and CD. Further, larger studies are required to confirm our findings.

Indexed as

AdultAgedAntibodies, Monoclonal, HumanizedCohort StudiesFemaleHumansIllinoisInflammatory Bowel DiseasesMaleMedical RecordsMiddle AgedPostoperative ComplicationsPreoperative PeriodPropensity ScoreRetrospective StudiesSurgical Wound InfectionAntibodies, Monoclonal, Humanizedvedolizumab

Identifiers

PMID28719595
OpenAlexW2739452942

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.